Neurocrine Biosciences Inc. NBIX stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings.The company on Monday reported adjusted EPS of 70 cents, lower than the $1.20 reported a year ago, beating the consensus of 54 cents.Neurocrine reported sales of$572.6 million compared to $515.3 million a year ago, missing the consensus of$559.3 million.Ingrezza’s first-quarter 2025 net product sales were $545 million, representing an 8% year-over-year growth, dri ...